Molecular imaging of atherosclerosis

Current Cardiology Reports

Volumn 10, Issue 2, 2008, Pages 121-127

  Dunphy, Mark P S ^a   Strauss, H William ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTEGRIN; LIPID; RADIOISOTOPE; RADIUM; TRACER; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; LOW DENSITY LIPOPROTEIN; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; ANTIGEN PRESENTING CELL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B LYMPHOCYTE; COMPUTER ASSISTED TOMOGRAPHY; DENDRITIC CELL; DIAGNOSTIC PROCEDURE; DISEASE MARKER; ECHOGRAPHY; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; ISOTOPE LABELING; LIPID METABOLISM; MACROPHAGE; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; VASA VASORUM; VASCULAR LESION; ARTERIOSCLEROSIS; BIOTECHNOLOGY; HISTORY; IMMUNOLOGY; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SCINTISCANNING; VASCULAR SMOOTH MUSCLE;

ARTERIOSCLEROSIS; BIOTECHNOLOGY; FLUORODEOXYGLUCOSE F18; HISTORY, 20TH CENTURY; HUMANS; INFLAMMATION; INTEGRINS; LIPID METABOLISM; LIPOPROTEINS, LDL; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS;

EID: 44449176109     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0021-5     Document Type: Review

References (55)

1. Morawski AM, Winter PM, Crowder KC, et al.: Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med 2004, 51:480-486.
2. Kukreja N, Garcia-Garcia HM, Serruys PW: Invasive imaging techniques for the assessment of vulnerable plaque. Minerva Cardioangiol 2006, 54:603-617.
3. Dunphy MPS, Schoder H, Strauss HW: Radionuclide techniques for identifying vulnerable plaque. J Nucl Med 2007, 48:1753-1755.
4. Lees RS, Lees AM, Strauss HW: External imaging of human atherosclerosis. J Nucl Med 1983, 24:154-156.
5. Fischman AJ, Lees AM, Lees RS, et al.: Accumulation of native and methylated low density lipoproteins by healing rabbit arterial wall. Arteriosclerosis 1987, 7:361-366.
6. Shaish A, Keren G, Chouraqui P, et al.: Imaging of aortic atherosclerotic lesions by (125)I-LDL, (125)I-oxidized-LDL, (125)I-HDL and (125)I-BSA. Pathobiology 2001, 69:225-229.
7. Tsimikas S: Noninvasive imaging of oxidized low-density lipoprotein in atherosclerotic plaques with tagged oxidation-specific antibodies. Am J Cardiol 2002, 90(10C):22L-27L.
8. Narula J, Petrov A, Bianchi C, et al.: Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and negative charge-modified antibody fragments. Circulation 1995, 92:474-484.
9. Dietrich T, Perlitz C, Licha K, et al.: ED-B fibronectin (ED-B) can be targeted using a novel single chain antibody conjugate and is associated with macrophage accumulation in atherosclerotic lesions. Basic Res Cardiol 2007, 102:298-307.
10. Tepe G, Duda SH, Meding J, et al.: Tc-99m-labeled endothelin derivative for imaging of experimentally induced atherosclerosis. Atherosclerosis 2001, 157:383-392.
11. Johnstrom P, Rudd JH, Richards HK, et al.: Imaging endothelin ET(B) receptors using [18F]-BQ3020: In vitro characterization and positron emission tomography (microPET). Exp Biol Med 2006, 231:736-740.
12. Fischman AJ, Rubin RH, Khaw BA, et al.: Radionuclide imaging of experimental atherosclerosis with nonspecific polyclonal immunoglobulin G. J Nucl Med 1989, 30:1095-1100.
13. Ohtsuki K, Hayase M, Akashi K, et al.: Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: An autoradiographic study. Circulation 2001, 104:203-208.
14. Vallabhajosula S, Machac J, Knesaurek K, et al.: Imaging atherosclerotic macrophage density by positron emission tomography using F-18 fluorodeoxyglucose (FDG) [abstract]. J Nucl Med 1996, 37(Suppl):38P.
15. Dunphy MP, Freiman A, Larson SM, Strauss HW: Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med 2005, 46:1278-1284.
16. Zhao Y, Kuge Y, Zhao S, et al.: Comparison of (99m)Tcannexin A5 with (18)F-FDG for the detection of atherosclerosis in ApoE-/-mice. Eur J Nucl Med Mol Imaging 2007, 34:1747-1755.
17. Schafers M, Riemann B, Kopka K, et al.: Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004, 109:2554-2559.
18. Kolodgie FD, Petrov A, Virmani R, et al.: Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: A technique with potential for noninvasive imaging of vulnerable plaque. Circulation 2003, 108:3134-3139.
19. Hartung D, Sarai M, Petrov A, et al.: Resolution of apoptosis in atherosclerotic plaque by dietary modification and statin therapy. J Nucl Med 2005, 46:2051-2056.
20. Strauss HW, Mari C, Patt BE, Ghazarossian V: Intravascular radiation detectors for the detection of vulnerable atheroma. J Am Coll Cardiol 2006, 47(8 Suppl):C97-C100.
21. Virgolini I, O'Grady J, Lupattelli G, et al.: In vivo quantification of cholesterol content in human carotid arteries by quantitative gamma-camera imaging after injection of autologous low density lipoproteins (LDL). Int J Rad Appl Instrum 1992, 19:245-250.
22. Virgolini I, Rauscha F, Lupattelli G, et al.: Autologous low-density lipoprotein labelling allows characterization of human atherosclerotic lesions in vivo as to presence of foam cells and endothelial coverage. Eur J Nucl Med 1991, 18:948-951.
23. Hardoff R, Braegelmann F, Zanzonico P, et al.: External imaging of atherosclerosis in rabbits using an 123I-labeled synthetic peptide fragment. J Clin Pharmacol 1993, 33:1039-1047.
24. Munro JM, van der Walt JD, Munro CS, et al.: An immunohistochemical analysis of human aortic fatty streaks. Hum Pathol 1987, 18:375-380.
25. Jonasson L, Holm J, Skalli O, et al.: Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986, 6:131-138.
26. Aqel NM, Ball RY, Waldmann H, Mitchinson MJ: Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis 1984, 53:265-271.
27. Buono C, Pang H, Uchida Y, et al.: B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2004, 109:2009-2015.
28. Zhou X, Robertson AK, Hjerpe C, Hansson GK: Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:864-870.
29. Bobryshev YV, Lord RS: Detection of vascular dendritic cells accumulating calcified deposits in their cytoplasm. Tissue Cell 1998, 30:383-388.
30. Yilmaz A, Lochno M, Traeg F, et al.: Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004, 176:101-110.
31. Whitman SC, Rateri DL, Szilvassy SJ, et al.: Depletion of natural killer cell function decreases atherosclerosis in low-density lipoprotein receptor null mice. Arterioscler Thromb Vasc Biol 2004, 24:1049-1054.
32. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
33. Bobryshev YV, Lord RS: Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res 1998, 37:799-810.
34. Bobryshev YV, Lord RS: Expression of heat shock protein-70 by dendritic cells in the arterial intima and its potential significance in atherogenesis. J Vasc Surg 2002, 35:368-375.
35. Stocker R, Keaney JF, Jr: Role of oxidative modifications in atherosclerosis. Physiol Rev 2004, 84:1381-1478.
36. Heidenthal AK, Weber PC, Lottspeich F, Hrboticky N: The binding in vitro of modified LDL to the intermediate filament protein vimentin. Biochemical and biophysical research communications. 2000, 267:49-53.
37. Kishikawa H, Shimokama T, Watanabe T: Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human atherogenesis. Virchows Arch 1993, 423:433-442.
38. Stemme S, Holm J, Hansson GK: T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 1992, 12:206-211.
39. Ehlers S, Smith KA: Differentiation of T cell lymphokine gene expression: The in vitro acquisition of T cell memory. J Exp Med 1991, 173:25-36.
40. Stemme S, Rymo L, Hansson GK: Polyclonal origin of T lymphocytes in human atherosclerotic plaques. Lab Invest 1991, 65:654-660.
41. Swanson SJ, Rosenzweig A, Seidman JG, Libby P: Diversity of T-cell antigen receptor V beta gene utilization in advanced human atheroma. Arterioscler Thromb 1994, 14:1210-1214.
42. Caligiuri G, Nicoletti A, Poirier B, Hansson GK: Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002, 109:745-753.
43. Major AS, Fazio S, Linton MF: B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002, 22:1892-1898.
44. Galkina E, Kadl A, Sanders J, et al.: Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med 2006, 203:1273-1282.
45. Kietselaer BL, Reutelingsperger CP, Heidendal GA, et al.: Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004, 350:1472-1473.
46. Rudd JH, Warburton EA, Fryer TD, et al.: Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002, 105:2708-2711.
47. Breyholz HJ, Wagner S, Levkau B, et al.: A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo. Q J Nucl Med Mol Imaging 2007, 51:24-32.
48. Davies MJ, Richardson PD, Woolf N, et al.: Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993, 69:377-381.
49. Burke AP, Kolodgie FD, Farb A, et al.: Healed plaque ruptures and sudden coronary death: Evidence that subclinical rupture has a role in plaque progression. Circulation 2001, 103:934-940.
50. Libby P, Sukhova G, Lee RT, Galis ZS: Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995, 25(Suppl 2):S9-S12.
51. Xu Y, Wang L, Buttice G, et al.: Major histocompatibility class II transactivator (CIITA) mediates repression of collagen (COL1A2) transcription by interferon gamma (IFN-gamma). J Biol Chem 2004, 279:41319-41332.
52. Dinkelborg LM, Duda SH, Hanke H, et al.: Molecular imaging of atherosclerosis using a technetium-99m-labeled endothelin derivative. J Nucl Med 1998, 39:1819-1822.
53. Bobryshev YV, Babaev VR, Lord RS, Watanabe T: Cell death in atheromatous plaque of the carotid artery occurs through necrosis rather than apoptosis. In Vivo 1997, 11:441-452.
54. Madamanchi NR, Vendrov A, Runge MS: Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25:29-38.
55. Beer AJ, Haubner R, Sarbia M, et al.: Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006, 12:3942-3949.